INTRODUCTION AND AIMS: Docohexanoic acid (DHA), a dietary n-3 polyunsaturated fatty acid(PUFA n-3), have shown reduce all-cause mortality inhemodialysis patients (HD). This study aimed to evaluate whether DHA-supplementation modified inflammatory profile andmodulated response to erythropoiesis-stimulating-agents in HD. METHODS: Parallel-controlled clinical trial in 42 HD patients (men: 69%; aged:66.7615.5;DM:19%), randomized into 2 groups:intervention group (DHA,n¼21) and, control group (Control, n¼21) . Administration of DHA supplementation (645 mg DHA/3 timesper week, post-HD) for 2 months of follow-up. Assessment intra and inter-groups at baseline(0) and post-intervention(1) of clinical,-biochemical and nutrition-inflammatory parameters. Inflammation measured by Creactive protein(CRP), anemia control throughweekly dose of erythropoietin (Epo) and erythropoiesis -responsiveness index (ERI Pharmacovigilance, Spark Therapeutics, Philadelphia, PA, United States INTRODUCTION AND AIMS: Daprodustat, a novel hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor, is one of the emerging investigational products for the treatment of anemia associated with chronic kidney disease (CKD) currently in phase 3 trials. Daprodustat affects transcription of HIF-responsive genes including increasing erythropoietin (EPO) and vascular endothelial cell growth factor (VEGF). Increased plasma VEGF and EPO levels have been associated with the development of macular edema (ME), proliferative retinopathy (PR), and choroidal neovascularization (CNV). We evaluated the effect of daprodustat on plasma VEGF and EPO levels and the risk of associated ophthalmic conditions in two 24-week dose ranging studies in two different CKD populations, those on hemodialysis (HD) and those not on dialysis (ND). METHODS: Ophthalmic examinations were performed at baseline, study midpoint, and end of the study. Relevant ophthalmology-related exclusion criteria included untreated clinically significant ME or PR or history of central retinal vein occlusion (CRVO) within the preceding 4 months. Subjects with pre-existing treated CNV, PR (excluding CRVO) and ME were enrolled. Ocular adverse events of special interest (AESI) associated with increased VEGF and EPO levels, specifically ME, PR and CNV, were predefined and evaluated by blinded review in-stream. Plasma VEGF and EPO levels were measured at baseline and every 4 weeks through the end of the study. RESULTS: The HD study randomized 216 subjects who were receiving recombinant human erythropoietin (rhEPO), with 177 and 39 subjects being randomized to daprodustat or control, respectively. Two subjects (1.1%) in the daprodustat arm had an ocular AESI of ME recorded over the course of the study; none in the control arm had an ocular AESI. The ND study randomized 250 rhEPO naïve or rhEPO users, with 170 and 80 being randomized to daprodustat or control, respectively. Three subjects (1.8%) had an ocular AESI of ME and one subject (0.6%) had an ocular AESI of PR in the daprodustat arm compared with one (1.3%) ocular AESI of ME in the control arm. In both studies, in subjects receiving daprodustat, plasma VEGF levels were slightly increased but highly variable, while plasma EPO levels remained near the baseline. CONCLUSIONS: Across these two CKD populations, the number of protocol-specified ocular AESI was low in both groups, and a similar proportion of subjects developed these events. 24-week daprodustat use was associated with minimal effects on plasma VEGF and plasma EPO levels. Phase 3 studies are ongoing to better understand the ocular safety of chronic daprodustat therapy. However, hypersensitivity reactions can occur after treatment with these IV iron preparations. The exact mechanism behind these reactions has not been fully elucidated yet. Recently, it has been demonstrated that iron preparations have the ability to activate complement in vitro. We investigated whether IV iron also activates complement in vivo. METHODS: Plasma samples were collected from 80 patients that were treated for anemia with iron preparations, including 52 non-CKD (mostly anemic due to GI losses) and non-dialysis CKD, and 28 undergoing maintenance hemodialysis (HD). In the non-dialysis patients, samples were collected prior to, and 60 minutes after finishing IV iron treatment. In the HD patients, samples were collected during two consecutive sessions -one session without IV iron and one session where IV iron was administrated. Iron sucrose was given to the HD patients and non-dialysis (CKD or non-CKD) patients, while ferric carboxymaltose was given only to the latter ones. Finally, MBL, C1q, Properdine, Factor D, C3d/C3-ratios and C5b-9 were measured. RESULTS: In the anemic patients, IV iron induced complement activation since mean values of plasma sC5b-9 levels significantly increased 60 minutes after the iron infusion. In addition, Factor D levels were reduced after iron treatment in these patients, suggesting consumption due to alternative pathway activation. Similarly, in patients undergoing HD, increased sC5b-9 levels were found at the end of the HD session with iron treatment compared to the session without iron. CONCLUSIONS: In summary, these findings show that IV iron preparations induce complement activation in vivo, both in non-HD and HD patients. Furthermore, complement activation by IV iron seems to occur via the alternative pathway. However, the exact mechanism through which iron nanoparticles activate complement and how this traduces into inflammation or allergy remains to be elucidated. 
SaO005 ADMINISTRATION OF INTRAVENOUS IRON PREPARATIONS INDUCES COMPLEMENT ACTIVATION IN PATIENTS

